{"log_id": 806481853009549882, "direction": 0, "words_result_num": 49, "words_result": [{"probability": {"variance": 0.004802, "average": 0.975517, "min": 0.591879}, "location": {"width": 607, "top": 199, "height": 31, "left": 216}, "words": "多西他赛治疗间,如果患者发生发热性中性粒细胞减少,且中性粒细胞数目<50"}, {"probability": {"variance": 0.01531, "average": 0.932703, "min": 0.584914}, "location": {"width": 203, "top": 200, "height": 21, "left": 874}, "words": "持续1周以上,出现重度或"}, {"probability": {"variance": 0.01284, "average": 0.938989, "min": 0.471085}, "location": {"width": 801, "top": 231, "height": 29, "left": 180}, "words": "治积性皮肤反应或重度外周神经症状,多西他赛的剂量应由100mg/m2减至75mg/m2.及或75mg/m2减至"}, {"probability": {"variance": 0, "average": 0.99146, "min": 0.99146}, "location": {"width": 19, "top": 232, "height": 19, "left": 1061}, "words": "若"}, {"probability": {"variance": 0.018468, "average": 0.929013, "min": 0.491517}, "location": {"width": 409, "top": 264, "height": 28, "left": 184}, "words": "送者在60mg/m2剂量时仍然出现以上症状,应停止治疗"}, {"probability": {"variance": 0.010962, "average": 0.946766, "min": 0.713197}, "location": {"width": 120, "top": 300, "height": 21, "left": 180}, "words": "乳腺癌助化疗"}, {"probability": {"variance": 0.010049, "average": 0.948353, "min": 0.604513}, "location": {"width": 860, "top": 324, "height": 29, "left": 215}, "words": "在关键的临床研究中,接受乳腺辅助化疗的患名,出现并发性中性粒细胞减少包括中性粒细胞减少发生时间延长"}, {"probability": {"variance": 0.014773, "average": 0.93399, "min": 0.448497}, "location": {"width": 901, "top": 355, "height": 31, "left": 181}, "words": "发热性中性粒细胞减少,或感染),在所有以后的用药周期中,排荐预防使用GCSF如:第4天至第11天)。若患者持续"}, {"probability": {"variance": 0.002391, "average": 0.96527, "min": 0.810543}, "location": {"width": 530, "top": 392, "height": 24, "left": 181}, "words": "出现以上反应,应坚持使用GCSF,并将多西他赛剂量减少至60mgm"}, {"probability": {"variance": 0.017292, "average": 0.942522, "min": 0.486388}, "location": {"width": 867, "top": 421, "height": 26, "left": 215}, "words": "然而,临床实践中中性拉细胞减少可能较早出现。因此应权衡患者中性粒细胞减少的危险及当前使用的推荐剂员而使"}, {"probability": {"variance": 0.016627, "average": 0.926979, "min": 0.497195}, "location": {"width": 894, "top": 451, "height": 29, "left": 181}, "words": "用G-CSF如果使用GCSF.多西他赛剂应由75减至60mg/m2,发生3级或级口腔炎的患者应将剂造减f6Omgm3"}, {"probability": {"variance": 0.023878, "average": 0.904557, "min": 0.574029}, "location": {"width": 104, "top": 488, "height": 21, "left": 181}, "words": "联合顺铂治疗"}, {"probability": {"variance": 0.010492, "average": 0.943582, "min": 0.546885}, "location": {"width": 690, "top": 515, "height": 26, "left": 216}, "words": "对于起始剂量为多西他赛75mg/m2联合顺的患者,且前期疗程中曾出现血小板最低值<250"}, {"probability": {"variance": 0.000779, "average": 0.980278, "min": 0.923361}, "location": {"width": 102, "top": 516, "height": 20, "left": 976}, "words": "或曾出现发热"}, {"probability": {"variance": 0.018085, "average": 0.928143, "min": 0.446576}, "location": {"width": 900, "top": 546, "height": 28, "left": 184}, "words": "性中性粒胞减少,或善出现严重的非血液学毒性、下一疗程的多西他赛剂量应减为6Smg/m顺铂剂量调整,见其产品"}, {"probability": {"variance": 0, "average": 0.999813, "min": 0.999759}, "location": {"width": 37, "top": 582, "height": 22, "left": 184}, "words": "介绍"}, {"probability": {"variance": 0.012089, "average": 0.936041, "min": 0.608837}, "location": {"width": 332, "top": 610, "height": 24, "left": 217}, "words": "对干曲妥珠单抗剂量调整,见其产品说明书"}, {"probability": {"variance": 0.002063, "average": 0.968259, "min": 0.890111}, "location": {"width": 70, "top": 643, "height": 20, "left": 183}, "words": "特殊人群"}, {"probability": {"variance": 0.004743, "average": 0.962778, "min": 0.692228}, "location": {"width": 861, "top": 668, "height": 29, "left": 217}, "words": "肝功能有损的患者:根据100mg/m2多西他赛单药治疗的药代动力学数据,ALT和或AST超过正常值L限1.5倍"}, {"probability": {"variance": 0.009305, "average": 0.956795, "min": 0.430726}, "location": {"width": 888, "top": 701, "height": 27, "left": 190}, "words": "司时碱性磷酸酶超过正常值上限2.5倍的思者,多西他赛的推荐剂量为75ng/m(见【注意项】及【药代动力学】)。对"}, {"probability": {"variance": 0.013093, "average": 0.956161, "min": 0.350927}, "location": {"width": 900, "top": 732, "height": 28, "left": 185}, "words": "于血清胆红素超过正常值上限和或ALT及AST超过正常值上限3.5倍并伴有性磷酸酶超过正常值上限6倍的患者,除"}, {"probability": {"variance": 0.001085, "average": 0.97795, "min": 0.864205}, "location": {"width": 823, "top": 766, "height": 23, "left": 185}, "words": "非有严格的使用指征,否则不应使用,也无减量使用建议。无肝功能有损害患者接受多西他赛联合治疗的数据"}, {"probability": {"variance": 0.015896, "average": 0.938365, "min": 0.471824}, "location": {"width": 862, "top": 795, "height": 28, "left": 221}, "words": "临用前将多西他赛所对应的溶剂全部吸入对应的济液中,轻轻振摇混合均匀,将混合后的药瓶室温放置5分钟,然后"}, {"probability": {"variance": 0.018904, "average": 0.941316, "min": 0.3577}, "location": {"width": 897, "top": 825, "height": 25, "left": 186}, "words": "检溶液是否均匀澄明,根据计算病人所用药量,用注射器吸入混合液,注入5%葡萄糖注射液或0.9%化钠注射液的"}, {"probability": {"variance": 0.00472, "average": 0.967121, "min": 0.708052}, "location": {"width": 425, "top": 853, "height": 22, "left": 187}, "words": "射瓶或注射袋中,轻轻摇动,混合均匀,最终浓度不起过"}, {"probability": {"variance": 1e-06, "average": 0.998865, "min": 0.997787}, "location": {"width": 88, "top": 883, "height": 19, "left": 195}, "words": "【不良反应】"}, {"probability": {"variance": 0.010713, "average": 0.95601, "min": 0.491528}, "location": {"width": 620, "top": 906, "height": 25, "left": 220}, "words": "从以下单药及联合用药的患者中,收集了与多西他赛很可能或可能相关的不良反应"}, {"probability": {"variance": 0.001951, "average": 0.97523, "min": 0.811471}, "location": {"width": 590, "top": 938, "height": 27, "left": 226}, "words": "312名思者接受100mg/m2,以及121名患者接受75mg/m2多西他赛单药治疗"}, {"probability": {"variance": 0.012155, "average": 0.949603, "min": 0.58574}, "location": {"width": 449, "top": 972, "height": 25, "left": 228}, "words": "58名思者接受75mg/m2多西他赛联合阿霉素50mg/m2治疗"}, {"probability": {"variance": 0.005473, "average": 0.965519, "min": 0.604626}, "location": {"width": 439, "top": 1004, "height": 24, "left": 223}, "words": "406名忠者接受75mg/m2多西他赛联合顺铂75mg/m2治疗"}, {"probability": {"variance": 0.006471, "average": 0.958366, "min": 0.694224}, "location": {"width": 336, "top": 1038, "height": 21, "left": 221}, "words": "92名者接受多西他赛联合曲妥珠单抗治疗"}, {"probability": {"variance": 0.01572, "average": 0.959364, "min": 0.380963}, "location": {"width": 392, "top": 1069, "height": 22, "left": 222}, "words": "332名者接受多西他赛联合强的松或强的松龙治疗"}, {"probability": {"variance": 0.008568, "average": 0.955603, "min": 0.559018}, "location": {"width": 413, "top": 1099, "height": 25, "left": 220}, "words": "744名患者接受多西他赛与阿霉素及环磷酰胺联合治疗"}, {"probability": {"variance": 0.016823, "average": 0.940419, "min": 0.424165}, "location": {"width": 866, "top": 1128, "height": 26, "left": 221}, "words": "主要根据NCI通用毒性标准(3级=G3,3-4级=G3/4:4级=G4)及 COSTART术语来描述反应类型及严重程度部分"}, {"probability": {"variance": 0.011038, "average": 0.947905, "min": 0.488598}, "location": {"width": 890, "top": 1159, "height": 28, "left": 188}, "words": "表格中重度”系沿用较早完成的临床研究原始资料中的描述,是根据研究者的主观判定,其定义为3级和/或3-4级的不"}, {"probability": {"variance": 0.004751, "average": 0.959009, "min": 0.650223}, "location": {"width": 889, "top": 1194, "height": 24, "left": 188}, "words": "事件。频度定义为:常常见(>1/10),常见(>1/100.<1/10):不常见(>1/1000,<1/100):少见(>1/10000<1/1000)"}, {"probability": {"variance": 0.009279, "average": 0.933476, "min": 0.674907}, "location": {"width": 128, "top": 1228, "height": 21, "left": 188}, "words": "罕见(<1/10000"}, {"probability": {"variance": 0.011779, "average": 0.952222, "min": 0.567964}, "location": {"width": 412, "top": 1259, "height": 22, "left": 223}, "words": "在每个频度组按严重程度由高到低的顺序列出不良反应"}, {"probability": {"variance": 0.00722, "average": 0.962632, "min": 0.552408}, "location": {"width": 846, "top": 1292, "height": 23, "left": 223}, "words": "多西他赛单药治疗最常见报告的不良反应为:中性粒细胞减少[可逆转几不积(见【用法用量】及【注意事项】):"}, {"probability": {"variance": 0.006677, "average": 0.963736, "min": 0.619961}, "location": {"width": 897, "top": 1322, "height": 27, "left": 188}, "words": "减少至最低点的中位时间为7天,发生重度中性粒细胞减少(<500m3)的中位持续时间为7天]贫血、脱发、心、呕"}, {"probability": {"variance": 0.003172, "average": 0.97578, "min": 0.70265}, "location": {"width": 773, "top": 1357, "height": 23, "left": 189}, "words": "吐、以腔炎、腹泻和弱。当多西他与其它化疗药物联合使用时可增加多西他赛不良事件的严重程度"}, {"probability": {"variance": 0.009022, "average": 0.936255, "min": 0.651872}, "location": {"width": 853, "top": 1390, "height": 23, "left": 223}, "words": "在联合妥珠单抗治疗中,列出≥10%的不良事件(所有级别)报告。在曲妥珠单抗联合组对比多两他赛单药,SAE"}, {"probability": {"variance": 0.008734, "average": 0.966999, "min": 0.53835}, "location": {"width": 448, "top": 1421, "height": 24, "left": 187}, "words": "发生岸(40%比31%)及4级AE(34%比23%)的发生增高"}, {"probability": {"variance": 0.001971, "average": 0.978217, "min": 0.844359}, "location": {"width": 211, "top": 1454, "height": 21, "left": 189}, "words": "多西他赛常见不良反应如下"}, {"probability": {"variance": 0.001994, "average": 0.973413, "min": 0.874225}, "location": {"width": 106, "top": 1484, "height": 22, "left": 189}, "words": "免疫系统异常"}, {"probability": {"variance": 0.011574, "average": 0.960076, "min": 0.444359}, "location": {"width": 861, "top": 1515, "height": 24, "left": 227}, "words": "过敏反应大多发生在多西他赛开始输注的最初几分钟内,通常是轻度至中度的。最常报告的症状是伴或不伴有症痒的"}, {"probability": {"variance": 0.025699, "average": 0.892757, "min": 0.488333}, "location": {"width": 879, "top": 1546, "height": 25, "left": 207}, "words": "斑及皮疹,胸闷,背痛,呼吸困难及药物性发热或寒颤。重度反应包括,低血压和或支气管痉或全身皮疹/红斑、停"}, {"probability": {"variance": 0.004592, "average": 0.9706, "min": 0.686954}, "location": {"width": 402, "top": 1580, "height": 26, "left": 186}, "words": "止输注进行对症治疗后即可恢复(见【注意事项】)。"}, {"probability": {"variance": 0.000119, "average": 0.992035, "min": 0.968337}, "location": {"width": 108, "top": 1613, "height": 23, "left": 188}, "words": "神经系统异常"}], "language": 3}